登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07502300,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Patients with histopathologically and/or cytologically confirmed extensive-stage small cell lung cancer;
入选标准第 5 条
Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
入选标准第 8 条
Use of immunomodulatory drugs within 14 days prior to the first dose of the study drug;
排除标准第 4 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
入选标准第 4 条
Must have at least one measurable lesion as defined by RECIST v1.1;
入选标准第 7 条
Diagnosis of active malignancy within 3 years prior to study randomization;
排除标准第 10 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07502300,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily sign the informed consent form and comply with the protocol requirements; Age ≥ 18 years; Expected survival time ≥ 3 months; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Patients with histopathologically and/or cytologically confirmed extensive-stage small cell lung cancer; Agree to provide archived tumor tissue specimens from the primary or metastatic lesions within 3 years, or fresh tissue samples; Must have at least one measurable lesion as defined by RECIST v1.1; Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0; No severe cardiac dysfunction, with left ventricular ejection fraction ≥ 50%; Organ function levels must meet the requirements; Urinary protein ≤ 2+ or < 1000 mg/24h; For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, and the serum pregnancy test must be negative; patients must not be breastfeeding. All enrolled patients (regardless of male or female) must use adequate barrier contraception throughout the entire treatment period and for 6 months after the end of treatment.排除标准:Exclusion Criteria:
Pathology indicates small cell carcinoma containing non-small cell carcinoma components; Patients who have previously received systemic treatment; Previous treatment with ADC drugs where the small molecule toxin is a topoisomerase I inhibitor; Use of immunomodulatory drugs within 14 days prior to the first dose of the study drug; History of severe heart disease or cerebrovascular disease; Receiving long-term systemic corticosteroid therapy at a dose >10 mg/day of prednisone or equivalent prior to the first dose; Active autoimmune diseases and inflammatory diseases; Unstable thrombotic events requiring therapeutic intervention within 6 months prior to screening; Prolonged QT interval, complete left bundle branch block, etc.; Diagnosis of active malignancy within 3 years prior to study randomization; Hypertension inadequately controlled with two antihypertensive medications; Poorly controlled diabetes mellitus; History of interstitial lung disease (ILD)/pneumonitis requiring steroid therapy, etc.; Concurrent pulmonary disease resulting in clinically severe impairment of respiratory function; Patients with active central nervous system (CNS) metastases; Severe infection within 4 weeks prior to study randomization; Presence of large serous cavity effusions, or serous cavity effusions with symptoms, etc.; Imaging findings indicating tumor invasion or encasement of major blood vessels in the abdomen, chest, neck, or pharynx; Severe, non-healing wound, ulcer, or bone fracture within 4 weeks prior to signing informed consent; Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent; Patients with inflammatory bowel disease, history of extensive bowel resection, history of immune-related enteritis, intestinal obstruction, or chronic diarrhea; History of allergy to recombinant humanized antibodies or any excipient component of BL-B01D1; History of autologous or allogeneic stem cell transplantation; Positive for human immunodeficiency virus antibody, active hepatitis B virus infection, or hepatitis C virus infection; History of severe neurological or psychiatric disorders; Receipt of other unapproved clinical study drugs or treatments within 4 weeks prior to study randomization; Subjects planning to receive or having received live vaccines within 28 days prior to study randomization; Other conditions deemed by the investigator to make the subject unsuitable for participation in this clinical trial due to complications or other circumstances.
引自 ClinicalTrials.gov, NCT07502300, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07502300,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。